Deutsche Bank’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$120K Sell
22,495
-3,343
-13% -$17.7K ﹤0.01% 3303
2026
Q2
$125K Buy
+25,838
New +$111K ﹤0.01% 3423
2024
Q1
– Sell
-39,472
Closed -$809K – 3613
2023
Q4
$809K Buy
+39,472
New +$660K ﹤0.01% 2132
2023
Q2
– Sell
-6,815
Closed -$67.3K – 3809
2023
Q1
$67.3K Buy
6,815
+2,026
+42% +$22.5K ﹤0.01% 3474
2022
Q4
$45.6K Buy
4,789
+2,903
+154% +$38.9K ﹤0.01% 3602
2022
Q3
$33K Sell
1,886
-310
-14% -$3.61K ﹤0.01% 3684
2022
Q2
$17K Buy
+2,196
New +$29.1K ﹤0.01% 3954

Other funds holding ANTX

Deutsche Bank's ANTX Position: Q3 2026 in Review

Deutsche Bank reduced its AN2 Therapeutics (ANTX) stake by 13% in Q3 2026, selling an estimated $17.7K and leaving 22,495 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #3303.

Deutsche Bank first reported a position in ANTX in Q2 2022 and has held it in 7 quarters since. The position peaked at $809K in Q4 2023. 88 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Deutsche Bank held 22,495 shares of AN2 Therapeutics worth $120K as of Q3 2026.
  • Deutsche Bank sold 3,343 AN2 Therapeutics shares in Q3 2026, an estimated $17.7K.
  • AN2 Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3303 holding.
  • Deutsche Bank first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • Deutsche Bank's AN2 Therapeutics position peaked at $809K in Q4 2023.
  • 88 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.